Click here to go to the previous page
Building International Competence in Drug Development Teams
Program Code:
173
Date:
Monday, June 25, 2012
Time:
3:30 PM to 5:00 PM
EST
CHAIR
:
Mary Murray,
Bristol-Myers Squibb Company, United States
Mary is responsible for supporting global clinical development efforts by building relationships with advocacy organizations and diverse patient and provider communities to keep them informed, educated and prepared to support clinical development of BMS compounds.
|
PRESENTER
(S):
Coordinator and Professor of Pharmaceutical Medicine Post-Graduation at Federal University of Sao Paulo. CEO Trials Consulting
|
Dr. Andrei Kravchenko studied Medicine and has PhD in dermatology. He started as CRA in 2002. In 2003 took the position of Clinical Trial Manager. From end of 2007 he is heading Ukrainian office of international CRO Harrison Clinical Research and is resposible for operations and business development
|
Mary Murray,
Bristol-Myers Squibb Company, United States
Mary is responsible for supporting global clinical development efforts by building relationships with advocacy organizations and diverse patient and provider communities to keep them informed, educated and prepared to support clinical development of BMS compounds.
|
Junichi Nishino, Novartis Pharma K.K., Japan
Description
This symposium introduces learning tools and concepts employed to develop the capabilities needed among a global clinical staff through different drug development stages. Special emphasis is placed on training requirements and strategies to advance drug development in Japan and the BRICT countries (Brazil, Russia, India, China, Turkey). Presenters offer case studies, lessons learned experiences and a job aid to help participants design and develop their own training programs for clinical staff and regulatory scientists.
Learning Objectives:
Define components and information sources to design a blended learning program focusing on drug development in the BRICT countries
Identify the key competencies clinical research staff and regulatory scientists need to excel in drug development
Discuss case studies as they relate to one's own experience.